Insulet Corp
NASDAQ:PODD

Watchlist Manager
Insulet Corp Logo
Insulet Corp
NASDAQ:PODD
Watchlist
Price: 260.27 USD -1.74% Market Closed
Market Cap: 18.3B USD

Insulet Corp
Investor Relations

Insulet Corporation has carved out a significant niche in the medical device industry, distinguishing itself through its innovative approach to diabetes management. The company is best known for its Omnipod Insulin Management System, a discreet, tubeless insulin pump that provides a solution for individuals with diabetes seeking an alternative to traditional insulin delivery methods. Unlike conventional pumps that require cumbersome tubes and significant patient involvement, the Omnipod system offers ease and convenience, allowing users more freedom and flexibility in their daily lives. The system operates via a small wearable pod that delivers insulin over several days, which users control remotely, removing much of the hassle associated with managing diabetes.

Insulet generates revenue by selling these pods and the associated Personal Diabetes Manager (PDM) devices, which together comprise the entire system. Customers typically purchase pods on a recurring basis, similar to a subscription model, which creates a steady stream of revenue for the company. The business model emphasizes continuous growth by expanding its user base and improving its technology to remain at the forefront of patient-centric diabetes care. Insulet's strategic focus on the needs of its users and commitment to refining their health technology has enabled it to build a sustainable business that addresses a critical healthcare challenge while also delivering consistent financial performance.

Show more
Loading

Earnings Calls

2024 Q2
Aug 28, 2024
Show Transcript
Previous
Next
AmpliTech Group Faces Challenges but Highlights 2025 Growth Potential
2024 Q2
Aug 28, 2024

In Q2 2024, AmpliTech reported a revenue of $2.5 million and a loss of $1.57 million, primarily due to reduced global demand and inflationary pressures. Despite challenging market conditions, the company maintains a healthy gross profit margin of 42%. Looking forward, CEO Fawad Maqbool anticipates that 75% to 80% of revenues in 2025 will come from 5G initiatives, driving optimism for future growth. The company estimates a $130 million pipeline, with expected revenue rerouted due to delays. Their new private 5G products include a full-service solution designed for diverse deployments, creating significant monetization opportunities across various sectors.

Show Full Analysis

Management

Ms. Lauren Budden
Group VP, Chief Accounting Officer & Controller
No Bio Available
Mr. Mark Field
Senior VP & CTO
No Bio Available
Mr. John Wodick Kapples J.D.
Senior VP & General Counsel
No Bio Available
Mr. Eric Benjamin
Executive VP, Chief Product & Customer Experience Officer
No Bio Available
Mr. Prem Singh
Senior Vice President of Global Operations
No Bio Available
Ms. Laetitia Cousin
Senior VP of Regulatory Affairs, Quality Assurance & Compliance
No Bio Available
Angela Geryak Wiczek
Senior Director of Corporate Communications
No Bio Available
Mr. Philip Hildale
Senior Vice President of Sales & Customer Care
No Bio Available
Mr. Andrew Isaacson
Senior VP of Strategy & Corporate Development
No Bio Available
Dr. Trang Ly
Senior VP & Chief Medical Officer
No Bio Available

Contacts

Address
MASSACHUSETTS
Acton
100 Nagog Park
Contacts
+19786007000.0
www.omnipod.com